Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respire Care Study of Luorunchang vs ambroxol oral solution in pediatric acute respiratory infection
ChiCTR2200055217Phase 4Recruiting
- Sponsor
- Jinan Children's Hospital
- Start
- Dec 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Luorunchang in acute respiratory illness (ARI) (2 arms), sponsored by Jinan Children's Hospital. Primary endpoint: Change in cough symptom score before and after treatment. Started Dec 2021; status: recruiting.
02
Drugs
Luorunchang
03
Conditions
acute respiratory illness (ARI)
Beyond the preview
Go deeper on ChiCTR2200055217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055217.